



## Article

The lysine methyltransferase SMYD2 is required for definite Hematopoietic Stem

Cell production in the mouse embryo






Figure S1. Assessment of vav-Cre conditional knockout efficiency of Smyd2. A. The presence of the flanked lox P sites on exon 2 of Smyd2 were confirmed via PCR. Lanes 1: Standard 1kb ladder followed by a non-template and additional controls. Upper panels: Cre recombination alleles. Middle panels: Smyd2. Lower panels: YFP (selectable marker). Primers:5'GGTCTGGCTTTGGAGTTGAGCC3'; 5'GAGCTTCGTGGAGTGCA GGAC3'. Conditions: 94°C x 5' (94°C x 30 min., 62°C x 30 min., 72°C x 30") x 35 min; cycles, 72°C x 7 min. **B**, **C**. The YFP marker utilized to measure the deletion efficiency 5'GGAGCGGGAGAAATGGATATG3'; of Smyd2 via PCR Primers: 5'AAAGTCGCTCTGAGTTGTTAT3';5'AAGACCGCGAAGAGTTTGTC3' Conditions: 94°C x 5 min (94° C x 30 min, 58° C x 1min, 72° C x 1min) x 35 cycles, 72° C x 7 min. All PCR products were analyzed via gel electrophoresis. 15ul of each sample and loading dye was run on a 2.0% agarose gel with the addition of ethidium bromide. Electrophoresis: 100v for ~30 min; visualization, UV. D, E. Representative Cre deletion efficiencies monitored in bone marrow and spleen via FACS analyses of YFPLSL. 100% of the cell sample population from either murine bone marrow or spleen viewed as side scatter (SSC) versus forward scatter (FSC). Left columns of each panel (Vav-Neg) are Smyd2flox/flox controls, whereas the right columns of each panel show percentages of Smyd2<sup>flox/flox</sup>Vav-Cre deletion. The internal YFP stop allele allows production of fluorescence following Smyd2 deletion prior to extracellular staining. BM deletion frequencies ranged from 75-88%, whereas splenic deletion frequencies ranged from 61-82%. .



**Figure S2. Analysis of hematopoietic populations following SMYD2 deletion with** *vav-Cre*. We crossed *Smyd*<sup>F/F</sup> mice with *Vav-Cre* mice (JAX stock #008610), which initiates recombination within E12.5 embryonic epithelium determined FACS profiles. Cells were sorted based on expression of YFP generated by crosses of *Rosa26-Lox-Stop-Lox-YFP* (YFP<sup>LSL</sup>) reporter mice (S-Fig.1). S-Figure 3 provides the stain combinations employed to identify population detection by flow cytometry. **A.** Lin-cKit+Sca1+ BM HSC adult BM HSC; **B.** CD19+CD43+cKit-IgM- BM pro-B cells; **C.** B220+CD19+CD43-IgM- BM large pre-B cells; **D.** B220+CD19+IgD-IgM+CD43- BM small pre-B cells; **E.** B220+CD19+IgD+ Splenic (Sp) mature B cells; **F.** IgM<sup>hi</sup>IgD<sup>how</sup> immature Sp B cells; IgM<sup>how</sup>IgD<sup>hi</sup> Sp mature B cells; IgM<sup>hi</sup>IgD<sup>hi</sup> transitional (Trans) Sp B cells. Total cell numbers were determined as: Total # femur/spleen/thymus cells harvested/sample X number of cells/gate. Statistical analyses performed by student's t-test on 4-6 experimental replicates; \*p≤0.05; \*\*p≤0.005; \*\*\*p≤0.001.

Tissue	Population	Population Abbr	Marker	Lineage
B o n e M a r r o w	Hematopoietic stem cell	HSC	Lin <sup>-</sup> Sca1 <sup>+</sup> ckit <sup>+</sup> Flt3 <sup>-</sup>	B220, CD19, CD3e, CD4,
	Multipotent progenitor	MPP	Lin <sup>-</sup> Sca1 <sup>+</sup> ckit <sup>+</sup> Flt3 <sup>int</sup>	CD8a, CD11b, Gr1, NK1.1,
	Lymphoid primed multipotent progenitor	LMPP	Lin <sup>-</sup> Sca1 <sup>+</sup> ckit <sup>+</sup> Flt3 <sup>hi</sup>	Ter119
	Common lymphoid progenitor	CLP	Lin <sup>-</sup> Flt3 <sup>+</sup> IL-7 <sup>+</sup> Sca1 <sup>low</sup> +ckit <sup>low</sup>	
	Common myeloid progenitor	СМР	Lin <sup>-</sup> Sca1 <sup>-</sup> +ckit <sup>+</sup> FcyR <sup>int</sup> CD34 <sup>int</sup>	
	Granulocyte/macrophage progenitor	GMP	Lin <sup>-</sup> Sca1 <sup>-</sup> +ckit <sup>+</sup> FcyR <sup>hi</sup> CD34 <sup>hi</sup>	
	Megakaryocyte/erythroid progenitor	MEP	Lin <sup>-</sup> Sca1 <sup>-</sup> +ckit <sup>+</sup> FcyR <sup>low</sup> CD34 <sup>low</sup>	
	Progenitor B cell	Pro-B	B220 <sup>+</sup> CD19 <sup>-</sup> CD43 <sup>+</sup> ckit <sup>+</sup> IgM <sup>-</sup>	
	Pre B cell	Pre-B	B220 <sup>+</sup> CD19 <sup>+</sup> CD43 <sup>-</sup> IgM <sup>-</sup>	
	Large Pre-B	Large Pre-B	B220 <sup>+</sup> CD19 <sup>+</sup> CD43 <sup>+</sup> IgM <sup>-</sup> BP1 <sup>+</sup>	
	Small Pre-B	Small Pre-B	B220 <sup>+</sup> CD19 <sup>+</sup> CD43 <sup>-</sup> IgM <sup>-</sup> CD2 <sup>+</sup>	
	Immature B cell	Imm B	B220 <sup>+</sup> CD19 <sup>+</sup> CD43 <sup>-</sup> IgM <sup>hi</sup> IgD <sup>-</sup>	
	Mature B cell or Recirculating B cell	Mat B or Recirc	B220 <sup>+</sup> CD19 <sup>+</sup> IgM <sup>hi</sup> IgD <sup>+</sup>	
	Macrophage	Macro	Mac1 <sup>+</sup> Gr1 <sup>low</sup> CD115 <sup>+</sup>	
	Granulocytes	Gran	Mac1 <sup>+</sup> Gr1 <sup>hi</sup> CD115 <sup>-</sup>	
	Plasmacytoid dendritic cell	pDC	CD11b <sup>-</sup> CD11c <sup>low</sup> B220 <sup>+</sup> PDCA1 <sup>+</sup>	
T h y m u s	Double negative	DN	CD4 <sup>-</sup> CD8 <sup>-</sup>	B220, CD19, CD3e, CD8a
	Double positive	DP	CD4 <sup>+</sup> CD8 <sup>+</sup>	TCRB, TCRy∆, CD11b, NK1.1,
	Helper T cells	CD4+	CD4 <sup>+</sup> CD8 <sup>-</sup>	Ly-6G, CD11b, CD11c,Ter119
	Cytotoxic T cells	CD8+	CD4 <sup>-</sup> CD8 <sup>+</sup>	
S p l e n	Immature B cell	Imm B	B220 <sup>+</sup> CD19 <sup>+</sup> IgM <sup>hi</sup> IgD <sup>-</sup>	
	Transitional B cell 1	Trans B 1	B220 <sup>+</sup> CD19 <sup>+</sup> IgM <sup>hi</sup> IgD <sup>-</sup> CD21 <sup>-</sup> CD23 <sup>-</sup>	
	Transitional B cell 2	Trans B 2	B220 <sup>+</sup> CD19 <sup>+</sup> IgM <sup>hi</sup> IgD <sup>+</sup> CD21 <sup>+</sup> CD23 <sup>+</sup>	
	Mature B cell or Recirculating B cell	Mat B or Recirc	B220 <sup>+</sup> CD19 <sup>+</sup> IgM <sup>hi</sup> IgD <sup>hi</sup>	
	Follicular B cell	FO B	B220 <sup>+</sup> CD19 <sup>+</sup> CD21 <sup>int</sup> CD23 <sup>hi</sup>	
	Marginal zone B cell	MZ B	B220 <sup>+</sup> CD19 <sup>+</sup> CD21 <sup>hi</sup> CD23 <sup>low</sup>	

**Figure S3.** Hematopoietic population definitions and antibody conjugates employed for their detection by flow cytometry. Sources of antibodies noted in S-Methods.



**Figure S4.** Protein deletion efficacy. Western blotting confirms reduction of SMYD2 in CKO detected by anti-SMYD2 serum relative to WT. Protein lysates were prepared and fractionated as previously described [11] on 12.5% SDS-PAGE. Following transfer to nylon, individual lanes were excised and blotted with the following commercial anti-human (h) antibodies: Anti-SMYD2 (ab108217; Abcam); and anti-GAPDH (ab181602; Abcam). After SDS-PAGE and transfer to nitrocellulose, blots were blocked with BSA (10% w/v), and then developed by chemiluminescence (Clarity Western ECL Substrate, Bio-Rad) with exposure time based on brightness of bands.